JOP20210260A1 - مثبطات كيناز تيروسين مستقبل عامل نمو الأرومة الليفية لمعالجة كارسينوما الظهارة البولية - Google Patents

مثبطات كيناز تيروسين مستقبل عامل نمو الأرومة الليفية لمعالجة كارسينوما الظهارة البولية

Info

Publication number
JOP20210260A1
JOP20210260A1 JOP/2021/0260A JOP20210260A JOP20210260A1 JO P20210260 A1 JOP20210260 A1 JO P20210260A1 JO P20210260 A JOP20210260 A JO P20210260A JO P20210260 A1 JOP20210260 A1 JO P20210260A1
Authority
JO
Jordan
Prior art keywords
treatment
urothelial carcinoma
tyrosine kinase
kinase inhibitors
fgfr
Prior art date
Application number
JOP/2021/0260A
Other languages
English (en)
Inventor
Porre Peter Marie Z De
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of JOP20210260A1 publication Critical patent/JOP20210260A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الاختراع الحالي بطرق موصوفة هنا لمعالجة كارسينوما الظهارة البولية بمنتج عقار معتمد يحتوي على مثبط مستقبل عامل نمو الأرومة الليفية (FGFR). وتُوصف هنا أيضًا طرق لبيع أو لعرض منتج عقار معتمد للبيع يحتوي على مثبط مستقبل عامل نمو الأرومة الليفية.
JOP/2021/0260A 2019-03-29 2020-03-27 مثبطات كيناز تيروسين مستقبل عامل نمو الأرومة الليفية لمعالجة كارسينوما الظهارة البولية JOP20210260A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166429 2019-03-29
US201962833395P 2019-04-12 2019-04-12
PCT/EP2020/058814 WO2020201138A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Publications (1)

Publication Number Publication Date
JOP20210260A1 true JOP20210260A1 (ar) 2023-01-30

Family

ID=69954076

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0260A JOP20210260A1 (ar) 2019-03-29 2020-03-27 مثبطات كيناز تيروسين مستقبل عامل نمو الأرومة الليفية لمعالجة كارسينوما الظهارة البولية

Country Status (14)

Country Link
US (1) US20220175768A1 (ar)
EP (1) EP3946340A1 (ar)
JP (1) JP2022527482A (ar)
KR (1) KR20210143878A (ar)
CN (1) CN113645975A (ar)
AU (1) AU2020253054A1 (ar)
BR (1) BR112021019203A2 (ar)
CA (1) CA3130773A1 (ar)
IL (1) IL286727A (ar)
JO (1) JOP20210260A1 (ar)
MA (1) MA55486A (ar)
MX (1) MX2021011943A (ar)
SG (1) SG11202109854RA (ar)
WO (1) WO2020201138A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202333720A (zh) 2021-10-12 2023-09-01 美商塔里斯生物醫學有限責任公司 用於膀胱內施用的厄達替尼調配物及系統
KR20240145513A (ko) 2022-02-18 2024-10-07 타리스 바이오메디컬 엘엘씨 에르다피티닙 제형 및 방광내 투여를 위한 삼투성 시스템
WO2024173377A1 (en) 2023-02-13 2024-08-22 Taris Biomedical Llc Erdafitinib for intravesical administration for use in the treatment of bladder cancer
WO2024173716A1 (en) 2023-02-17 2024-08-22 Taris Biomedical Llc Erdafitinib for intravesical administration for use in the treatment of bladder cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
MX2007014782A (es) 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
HUE058219T2 (hu) 2014-09-26 2022-07-28 Janssen Pharmaceutica Nv FGFR-mutánsgénpanel alkalmazása olyan rákbetegek azonosításában, akik FGFR-inhibitorral történõ kezelésre reszponzívak lesznek
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment

Also Published As

Publication number Publication date
EP3946340A1 (en) 2022-02-09
AU2020253054A1 (en) 2021-09-30
BR112021019203A2 (pt) 2021-11-30
JP2022527482A (ja) 2022-06-02
US20220175768A1 (en) 2022-06-09
MA55486A (fr) 2022-02-09
CA3130773A1 (en) 2020-10-08
CN113645975A (zh) 2021-11-12
WO2020201138A1 (en) 2020-10-08
MX2021011943A (es) 2021-11-03
SG11202109854RA (en) 2021-10-28
KR20210143878A (ko) 2021-11-29
IL286727A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
JOP20210260A1 (ar) مثبطات كيناز تيروسين مستقبل عامل نمو الأرومة الليفية لمعالجة كارسينوما الظهارة البولية
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
CA2983481A1 (en) Janus kinase inhibitor
MX2016012097A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
MX2021015826A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
MX2016010106A (es) Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos.
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
AU2018284249A1 (en) Aminothiazole compounds as protein kinase inhibitors
MX2020011344A (es) Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
MX2023011608A (es) Metodos para inhibir ras.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2021013602A (es) Inhibidores de jak.
MX2023013912A (es) Metodos para inhibir ras.
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2020005342A (es) Compuestos de pirazolopiridinona.
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.
MX2022005991A (es) Farmaco combinado.
EA202192643A1 (ru) Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы
MX2022001702A (es) Inhibidores de jak.
MX2023005716A (es) Derivados de cromeno como inhibidores de la interaccion receptor de antigeno de celula t (tcr) - region no catalitica de la proteina citosolica de la proteina tirosina cinasa (nck).
MX2021007853A (es) Compuestos de tienopiridinona.
EP3923947A4 (en) FGFR INHIBITORS FOR THE TREATMENT OF CANCER